Empower Hope: Donate for Neurological Disorders Research Today!
Your donation fuels breakthroughs and treating neurological disorders. Be a catalyst for change. Donate now via IDIBELL or Miquel Valls Foundation to NeuroHubLab!
The Neurology hub Laboratory (NeuroHubLab) is the research laboratory of the Neurology Service of the Bellvitge University Hospital, and it is integrated within the Neurological Diseases and Neurogenetic Group from the Bellvitge University Hospital and the Bellvitge Biomedical Research Institute (IDIBELL). We are a basic and translational laboratory focused on cutting-edge research, aimed at understanding, diagnosing, and finding effective treatments for various neurological disorders that affect the brain, spinal cord, and nervous system.
At our laboratory, we bring together a team of skilled neuroscientists, clinicians, bioinformaticians, and technicians who work collaboratively to unravel the complexities of neurologic diseases. Our mission is to advance the frontiers of neuroscience, improve patient care, and ultimately make a positive impact on the lives of those affected by these conditions.
Increased CXCL12, a potential CSF biomarker for differential diagnosis of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is a debilitating and lethal neurodegenerative disorder marked by the gradual deterioration of motor neurons. Diagnosing ALS is challenging due to the lack of reliable diagnostic tools, with clinical assessment being the primary criterion. Recently, increased levels of NF-L in CSF have been considered a useful biomarker in disease, correlating with disease progression but not specific for diagnosis. This study utilized enzyme-linked immunosorbent assay to measure CSF CXCL12 levels in healthy controls, ALS patients and patients with ALS-mimic disorders, assessing its potential as a diagnostic biomarker and comparing it with NF-L levels.
Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen
The objective of this study is to evaluate biomarkers for neurodegenerative disorders in adult SMA patients and their potential for monitoring the response to nusinersen. The slow progression rate and mild treatment response of adult SMA types 2 and 3 may not lead to detectable changes in common markers of axonal degradation, inflammation, or neurodegeneration, since it does not involve large pools of damaged neurons as observed in pediatric forms. However, changes in biomarkers associated with the APP processing pathway might be linked to treatment administration. Further studies are warranted to better understand these findings.
Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort
This proof-of-concept study comparing benign and aggressive RRMS groups reinforces the potential role of baseline NfL serum levels as a promising long-term disability prognostic marker. In contrast, serum GFAP, total tau, and CHI3L1 levels demonstrated a lower or no ability to differentiate between the long-term outcomes of RRMS.
Proteostatic modulation in brain aging without associated Alzheimer’s disease-and age-related neuropathological changes
(Phospho)proteomics of old-aged subjects without cognitive or behavioral symptoms, and without AD-neuropathological changes and lacking any other neurodegenerative alteration will increase understanding about the physiological state of human brain aging without associate neurological deficits and neuropathological lesions.
Deregulated Transcription and Proteostasis in Adult mapt Knockout Mouse
Transcriptomics and phosphoproteomics were carried out in the cerebral cortex of B6.Cg-Mapttm1(EGFP)Klt (tau knockout: tau-KO) and wild-type (WT) 12 month-old mice to learn about the effects of tau ablation. Compared with WT mice, tau-KO mice displayed reduced anxiety-like behavior and lower fear expression
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
Natalizumab (NTZ) and ocrelizumab (OCR) can be used for the treatment of relapsing–remitting multiple sclerosis (RRMS). In patients treated with NTZ, screening for JC virus (JCV) is mandatory, and a positive serology usually requires a change in treatment after 2 years. In this study, JCV serology was used as a natural vexperiment to pseudo-randomize patients into NTZ continuation or OCR.
Voiceprint and machine learning models for early detection of bulbar dysfunction in ALS
Bulbar dysfunction is a term used in amyotrophic lateral sclerosis (ALS). It refers to motor neuron disability in the corticobulbar area of the brainstem which leads to a dysfunction of speech and swallowing. One of the earliest symptoms of bulbar dysfunction is voice deterioration char- acterized by grossly defective articulation, extremely slow laborious speech, marked hypernasality and severe harshness.
